The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between October 1, 2020 and March 10, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before June 2, 2021.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Kadmon submitted a New Drug Application (“NDA”) for belumosudil for the treatment of cGVHD to the FDA that was incomplete and deficient. When the Company submitted additional data to the FDA in response to the agency’s request, it materially changed the NDA submission. The FDA was likely to extend the Prescription Drug User Fee Act (“PDUFA”) target action date to review the Company’s NDA. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Kadmon, investors suffered damages.
The Schall Law Firm
Brian Schall, Esq.,